Genetic and pharmacological inactivation of soluble epoxide hydrolase ameliorates diet-induced MASH

BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH) is the most common chronic liver disease worldwide. Pharmacological interventions for MASH remain limited, establishing the need to identify and validate novel therapeutic targets. Soluble epoxide hydrolase (sEH; EPHX2) hydrolyzes anti-inflammatory epoxy fatty acids into less bioactive diols. METHODS: ) either regular chow or a fructose-supplemented fast-food diet (FFD) for 27 weeks. We evaluated metabolic parameters and markers of liver injury, steatosis, inflammation, and fibrosis, as well as oxylipin profiling. Moreover, we treated FFD-fed control mice with the sEH pharmacological inhibitor TPPU in preventive, early, and late therapeutic intervention modalities. RESULTS: We report significant elevation in hepatic EPHX2 in MASH patients compared with controls. Hepatic sEH deficiency improved glucose tolerance, with trends toward lower fasting glucose and fed insulin levels, independent of body weight. Remarkably, hepatic sEH deficiency ameliorated FFD-induced liver injury, steatosis, and lipid dysregulation. Additionally, sEH deficiency mitigated hepatic and systemic inflammation and fibrosis triggered by prolonged FFD feeding. Furthermore, sEH deficiency remodeled the hepatic oxylipin profile and preserved anti-inflammatory epoxides. Importantly, sEH pharmacological inhibition recapitulated these findings, significantly reducing liver injury and steatosis, inflammation, and fibrosis in the FFD across preventive and therapeutic intervention modalities, with the greatest effect in the preventive arm. CONCLUSIONS: Together, these findings establish that genetic and pharmacological inactivation of sEH rebalances the oxylipin landscape, enhances the metabolic profile, and ameliorates steatosis, inflammation, and fibrosis in a dietary mouse model of MASH. The concordance between the genetic and pharmacological approaches, along with the efficacy of sEH inhibition across preventive and therapeutic modalities, supports developing sEH-targeted interventions for MASH.

Authors

Institutions

Publication Details

Journal
Journal of Biomedical Science
Published
2026-11-16
DOI
https://doi.org/10.1186/s12929-026-01294-3
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Genetic and pharmacological inactivation of soluble epoxide hydrolase ameliorates diet-induced MASH

Ming-Fo Hsu, Fawaz G. Haj, Jun Yang, Aline Mello et al.
1 links
Journal of Biomedical Science
Liver Disease Diagnosis and Treatment
article

Genetic and pharmacological inactivation of soluble epoxide hydrolase ameliorates diet-induced MASH

Ming-Fo Hsu, Fawaz G. Haj, Jun Yang, Aline Mello, Bruce Hammock, Natalie Torok
article en

Abstract

BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH) is the most common chronic liver disease worldwide. Pharmacological interventions for MASH remain limited, establishing the need to identify and validate novel therapeutic targets. Soluble epoxide hydrolase (sEH; EPHX2) hydrolyzes anti-inflammatory epoxy fatty acids into less bioactive diols. METHODS: ) either regular chow or a fructose-supplemented fast-food diet (FFD) for 27 weeks. We evaluated metabolic parameters and markers of liver injury, steatosis, inflammation, and fibrosis, as well as oxylipin profiling. Moreover, we treated FFD-fed control mice with the sEH pharmacological inhibitor TPPU in preventive, early, and late therapeutic intervention modalities. RESULTS: We report significant elevation in hepatic EPHX2 in MASH patients compared with controls. Hepatic sEH deficiency improved glucose tolerance, with trends toward lower fasting glucose and fed insulin levels, independent of body weight. Remarkably, hepatic sEH deficiency ameliorated FFD-induced liver injury, steatosis, and lipid dysregulation. Additionally, sEH deficiency mitigated hepatic and systemic inflammation and fibrosis triggered by prolonged FFD feeding. Furthermore, sEH deficiency remodeled the hepatic oxylipin profile and preserved anti-inflammatory epoxides. Importantly, sEH pharmacological inhibition recapitulated these findings, significantly reducing liver injury and steatosis, inflammation, and fibrosis in the FFD across preventive and therapeutic intervention modalities, with the greatest effect in the preventive arm. CONCLUSIONS: Together, these findings establish that genetic and pharmacological inactivation of sEH rebalances the oxylipin landscape, enhances the metabolic profile, and ameliorates steatosis, inflammation, and fibrosis in a dietary mouse model of MASH. The concordance between the genetic and pharmacological approaches, along with the efficacy of sEH inhibition across preventive and therapeutic modalities, supports developing sEH-targeted interventions for MASH.

Journal of Biomedical ScienceVol. 33(1)
Stanford Medicine (US), University of California Davis Medical Center (US), UC Davis Comprehensive Cancer Center (US), University of California, Davis (US), Stanford University (US)
Nora Eccles Treadwell Foundation, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, University of California, Davis, National Institute of Environmental Health Sciences
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon